Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal
نویسندگان
چکیده
Statement of Interest: J.B. Morjaria has received honoraria for speaking and financial support to attend meetings from Chiesi, Pfizer, MSD, Boehringer Ingelheim and GSK. A.H. Morice has received honoraria for speaker meetings and financial support to attend meetings/advisory boards from Chiesi, Pfizer, MSD, Boehringer Ingelheim, Novartis, GSK, AstraZeneca, Proctor & Gamble Healthcare, Orion Respiratory UK, Vectura Ltd, and Nycomed.
منابع مشابه
Pulmonary Hypertension Registry: a 10-Year Experience
Background: Pulmonary Arterial Hypertension (PAH), a fatal orphan disease, is defined as increased mean Pulmonary Arterial Pressure (mPAP) above 25 mm/Hg, Pulmonary Capillary Wedge Pressure (PCWP) below 15 mm/Hg, and pulmonary vascular Resistance over 3 Wood Unit (WU). Although Pulmonary Hypertension (PH) is a relatively prevalent disease, the idiopathic form (iPAH) is a rare disease with a pre...
متن کاملA case of severe pulmonary hypertension associated with common arterial trunk and VSD in a 9 years old child
Background: Common arterial trunk (CAT) is a rare congenital heart disease, and often leads to the early development of pulmonary hypertension and disability. Among the critical structural heart defects, the frequency of CAT is 3%, which reflects the severe hemodynamic disturbances. The natural course of the disease is characterized by a high mortality rate up to 88% during the first year of li...
متن کاملTHE EFFECTS OF CAPTOPRIL ON PULMONARY AND SYS TEMIC ARTERIAL PRESSURES IN HIGHALTITUDE PULMONARY HYPERTENSION
The purpose of this investigation was to assess the effect of captopril on both systemic (P.a) and pulmonary arterial pressures (PPA) in patients with high-altitude pulmonary hypertension (HAPH). Seventeen patients (mean age 44±6.8 years) with HAPH and mild to moderate systemic arterial hypertension were included in the study. All patients underwent right heart catheterization with measurem...
متن کاملPrevalence and Risk Factors of Pulmonary Arterial Hypertension in Thalassemia Major Patients of Ilam, 2014
Pulmonary arterial hypertension (PAH) is a progressive disease with high morbidity and mortality rates. Research has shown that PAH has a prevalence rate of 10-79% in thalassemia major patients. This cross-sectional study was carried out in 2014 to determine the prevalence and risk factors of PAH in all thalassemia major patients of over 18 years of age in Ilam, Iran. A cardiologist measured sy...
متن کاملبررسی اثر تادالافیل خوراکی در کاهش پرفشاری شریان ریوی در کودکان و نوجوانان 5 ماهه تا 15 ساله
Introduction: Pulmonary arterial hypertension in children has consequences such as right ventricular failure and even death. Recently, the use of phosphodiesterase 5 inhibitors has been taken into account in the treatment of pulmonary hypertension, among which tadalafil is more acceptable by parents and patients due to its single dose per day compared to sildenafil which should be taken 4 times...
متن کامل